The resulting cells are purer and more abundant than any before and are functional. The time is therefore ripe for drug screening to enhance muscle regeneration and brown adipocytes activity.


The company has two main programs:


NCEs for muscle diseases with a first priority for DMD patients then sarcopenia and cachexia.

NCEs for metabolic diseases with a first priority for T2D then obesity.

The unique expertise of Anagenesis Biotechnologies in generating P2MCs from stem cells will allow us to rapidly build on our proof‐of‐concept muscle and BAT studies to generate other clinically significant tissues.

For more information on Anagenesis Biotechnologies products and on partnership opportunities, please contact us